

BULK ANTIBODIES

for *in vivo*

RESEARCH

α -PD-1

α -PD-L1

α -4-1BB

α -CTLA4

α -LAG3

Discover More

BioCell



The Journal of
Immunology

This information is current as
of November 14, 2019.

Identification of Naive or Antigen-Experienced Human CD8⁺ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8⁺ T Cell Response

Mark R. Wills, Georgina Okecha, Michael P. Weekes, Maher
K. Gandhi, Patrick J. G. Sissons and Andrew J. Carmichael

J Immunol 2002; 168:5455-5464; ;

doi: 10.4049/jimmunol.168.11.5455

<http://www.jimmunol.org/content/168/11/5455>

References This article **cites 26 articles**, 16 of which you can access for free at:
<http://www.jimmunol.org/content/168/11/5455.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2002 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Identification of Naive or Antigen-Experienced Human CD8⁺ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8⁺ T Cell Response¹

Mark R. Wills,² Georgina Okecha, Michael P. Weekes, Maher K. Gandhi, Patrick J. G. Sissons, and Andrew J. Carmichael

Human CMV (HCMV) infection provides an informative model of how long term human CD8⁺ T cell memory is maintained in the presence of Ag. To clarify the phenotypic identity of Ag-experienced human CD8⁺ T cells *in vivo*, we determined the expression of costimulation and chemokine receptors on Ag-specific CD8⁺ T cells by quantifying individual virus-specific clones in different cell populations using TCR clonotypic probing. In healthy HCMV carriers, expanded CD8⁺ clones specific for either HCMV tegument protein pp65 or immediate-early protein IE72 are found in both CD45RO^{high} cells and the subpopulation of CD45RA^{high} cells that lack the costimulatory molecule CD28. In contrast to previous suggested models of CD8⁺ T cell memory, we found that in healthy virus carriers highly purified CD28⁻CD45RA^{high}CCR7⁻ cells are not terminally differentiated, because following stimulation *in vitro* with specific HCMV peptide these cells underwent sustained clonal proliferation, up-regulated CD45RO and CCR5, and showed strong peptide-specific cytotoxic activity. In an individual with acute primary HCMV infection, HCMV pp65-specific CD8⁺ T cells are predominantly CD28⁻CD45RO^{high}CCR7⁻. During convalescence, an increasing proportion of pp65-specific CD8⁺ T cells were CD28⁻CD45RA^{high}CCR7⁻. We conclude that naive human CD8⁺ T cells are CD28⁺CD45RA^{high}, express CCR7 but not CCR6, and are predominantly CD27⁺ and L-selectin CD62 ligand-positive. The phenotype CD27⁺CD45RA^{high} should not be used to identify naive human CD8⁺ T cells, because CD27⁺CD45RA^{high} cells also contain a significant subpopulation of CD28⁻CD27⁺ Ag-experienced expanded clones. Thus CD8⁺ T cell memory to HCMV is maintained by cells of expanded HCMV-specific clones that show heterogeneity of activation state and costimulation molecular expression within both CD45RO^{high} and CD28⁻CD45RA^{high} T cell pools. *The Journal of Immunology*, 2002, 168: 5455–5464.

Following primary infection, the β -herpesvirus human CMV (HCMV)³ establishes life-long infection with viral latency in cells of the myeloid lineage and intermittent shedding of infectious virions from mucosal surfaces. T cells play a crucial role in the control of HCMV; in HCMV-infected individuals, impairment of T cell responses (e.g., in advanced HIV infection or in allograft recipients who receive immunosuppressive drugs) is frequently followed by uncontrolled HCMV reactivation that leads to serious disease. HCMV provides an informative model of how long-term human CD8⁺ T cell memory is maintained in presence of persistent viral Ag. Strong virus-specific CD8⁺ T cell responses develop during primary infection and are maintained indefinitely. Healthy HCMV carriers have large populations of circulating HCMV-specific CD8⁺ T cells, many of which recognize peptides derived from the virus structural protein pp65 (product of the *UL83* gene) (1) or the major immediate-early

(IE) proteins expressed in infected cells (2). The CD8⁺ T cell response against a defined HCMV peptide is typically dominated by relatively few individual clones that are greatly expanded and maintained in PBMC for long periods (3).

To understand the mechanisms by which T cell memory is generated and maintained, there is much interest in using the cell surface phenotype to distinguish between naive cells and Ag-experienced cells. For human T cells, it was initially proposed that expression of the high m.w. isoform of leukocyte common Ag, CD45RA, identified naive cells, whereas the low m.w. isoform, CD45RO, identified Ag-experienced cells (4, 5). However, analysis of the phenotypic distribution of Ag-specific CD8⁺ T cells in virus carriers using either TCR clonotypic probing or class I MHC tetramers incorporating HCMV or EBV peptides has clearly demonstrated that these Ag-specific cells are distributed in both the CD45RO^{high} and CD45RA^{high} populations (6, 7). In long-term HCMV carriers, cells of an individual HCMV-specific CD8⁺ T cell clone are present in both the CD45RA^{high} and CD45RO^{high} populations; the CD45RA^{high} population contributes 6- to 10-fold more than the CD45RO^{high} population to the total clone size in PBMC (8). The pool of CD45RA^{high} CD8⁺ T cells thus contains a mixture of naive cells and Ag-experienced cells. Hamman et al. (9) have proposed that CD45RA^{high} cells, which express the TNFR family member CD27, represent naive cells, and that CD45RA^{high}CD27⁻ cells, which have high levels of preformed perforin and shortened telomere length, are a terminally differentiated effector population. More recently, Sallusto et al. (10) described a subpopulation of CD45RA^{high}CD8⁺ T cells that express the chemokine receptor CCR7, which favors homing to lymph

Department of Medicine, University of Cambridge, Cambridge, United Kingdom

Received for publication December 17, 2001. Accepted for publication March 19, 2002.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by Medical Research Council Program Grant G9202171 (to J.G.P.S.) and a Medical Research Council Cooperative Group Grant. A.J.C. is a Lister Institute Research Fellow.

² Address correspondence and reprint requests to Dr. Mark Wills, Department of Medicine, University of Cambridge, Clinical School Hills Road, Cambridge, U.K. CB2 2QQ. E-mail address: mrw1004@cam.ac.uk

³ Abbreviations used in this paper: HCMV, human CMV; CD62L, CD62 ligand; IE, immediate-early; MIP-3 β , macrophage inflammatory protein-3 β ; TC, TriColor.

nodes through interaction with secondary lymphoid chemokine expressed on endothelial cells; these cells lack perforin, but upon stimulation produce large amounts of IL-2, but not IFN- γ . In contrast, CD45RA^{high}CCR7⁻ cells express perforin and upon stimulation produce little IL-2 (10). The CD45RA^{high}CD27⁻ cells characterized by Hamman et al. (9) appear to be a subpopulation within the CD45RA^{high}CCR7⁻ cells.

Using MHC class I tetramers incorporating peptides of HIV or HCMV to identify Ag-specific CD8⁺ T cells, Champagne et al. (11) found that tetramer-positive cells were present in both the CD45RA^{high}CCR7⁺ and CD45RA^{high}CCR7⁻ subpopulations of CD8⁺ T cells and suggested that CD45RA^{high}CCR7⁻ cells might be terminally differentiated effector cells. Faint et al. (12) reported that CD45RA^{high}CD8⁺ T cells show a bimodal distribution of CD11a expression, and Ag-specific CD8⁺ T cells (identified by MHC class I tetramers incorporating peptides of HCMV or EBV) were found within the CD11a^{high} subpopulation. They proposed that CD45RA^{high}CD11a^{low} cells are naive cells, and that CD45RA^{high}CD11a^{high} cells are a subset of Ag-experienced cells (12). Circulating melanoma specific CD8⁺ T cells have been described in patients with metastatic melanoma; MART-1-specific cells are predominantly CD45RO⁺, whereas tyrosinase-specific cells are predominantly CD45RA⁺ and express perforin, but appear to have impaired effector function in vivo (13, 14).

In this study, we found that expression of the costimulatory molecule CD28 distinguishes two populations within the CD45RA^{high} CD8⁺ T cell pool, and we used peptide-MHC tetramers and TCR clonotypic analysis to determine the distribution of virus-specific clones between the CD28⁺CD45RA^{high} and CD28⁻CD45RA^{high} subpopulations. We used four-color flow cytometry to analyze the expression of chemokine receptors and adhesion and costimulation molecules on the CD28⁺CD45RA^{high}, CD28⁻CD45RA^{high}, CD28⁺CD45RO^{high}, and CD28⁻CD45RO^{high} subpopulations. To determine whether CD8⁺CD45RA^{high}CCR7⁻ cells are terminally differentiated effector cells, we assessed the ability of purified CD8⁺CD45RO^{high} and CD8⁺CD45RA^{high}CCR7⁻ cells to respond to stimulation with specific viral peptide and observed strong proliferative and peptide-specific cytotoxic responses. Our results show that CD8⁺ T cell memory to HCMV is maintained by cells that show heterogeneity of activation state and costimulation molecule expression and are found within both the CD45RO^{high} and CD28⁻CD45RA^{high} T cell pools.

Materials and Methods

Donors

Seven healthy HCMV seropositive laboratory donors were studied, all of whom were also EBV seropositive. In addition, two further EBV seropositive laboratory donors were studied. One patient with primary HCMV infection was also studied, in whom the diagnosis was confirmed serologically by detection of HCMV-specific IgM and subsequent isotype switching to HCMV-specific IgG (Public Health Laboratory Service, Addenbrookes Hospital, Cambridge, U.K.).

Viral peptides

The following peptides of HCMV pp65 were used: NLVPMVATV (aa 495–503), restricted through HLA-A2; TPRVTGGGAM (aa 417–426), restricted through HLA-B7; EFFWDANDIY (aa 511–525), restricted through HLA-B44; and VFPTKDVAL (aa 187–195), restricted through HLA-B35 (all supplied by Affiniti Research Products (Exeter, U.K.); >95% pure by HPLC). Peptides of HCMV IE72 were: CRVLCYVYL (aa 309–317), restricted through HLA-B7; and DELRRKMMYM (aa 198–207), restricted through HLA-B8 (2) (both gifts from Dr. F. Kern, Charité, Humboldt University, Berlin, Germany). Peptides of EBV EBNA3C were: EENLLDFVRF (aa 281–290), restricted through HLA-B44.02; and PQRAPIRPIPT (aa 880–891), restricted through HLA-B7 (supplied by Af-

Table I. Viral peptides and MHC class I restriction used in this study

Viral Protein	Peptide	HLA Restriction
HCMV pp65	NLVPMVATV aa 495–503	A*0201
HCMV pp65	TPRVTGGGAM aa 417–426	B*0702
HCMV pp65	EFFWDANDIY aa 511–525	B*4402
HCMV pp65	VFPTKDVAL aa 187–195	B*3503
HCMV IE72	CRVLCYVYL aa 309–317	B*0702
HCMV IE72	DELRRKMMYM aa 198–207	B*0801
EBV EBNA3c	EENLLDFVRF aa 281–290	B*4402
EBV EBNA3c	PQRAPIRPIPT aa 880–891	B*0702

finiti Research Products). All peptides were dissolved in RPMI and used at a 40 μ g/ml final concentration (Table I).

mAbs and surface phenotype analysis

mAbs were specific for CD3, CD4, CD8, CD14, CD16, CD19, CD25, CD27, CD28, CD45RO, CD45RA, CD56, CD57, CD62 ligand (CD62L), and HLA-DR (TCS Biologicals, Burlingdale, CA); anti-TCR V β 3, -11, -13.1, -14, and -17 (Immunotech); and anti-chemokine receptors CXCR4, CCR5, CCR6, and CCR7 (BD Biosciences, Oxford, U.K.). Abs were conjugated to FITC, PE, TriColor (TC), or allophycocyanin. Because the anti-CCR7 was an unconjugated IgM, cells were stained with anti-IgM biotin (BD PharMingen), washed, and then further stained with streptavidin-Red 670 (Life Technologies, Paisley, U.K.). Before immunostaining for four-color analysis, CD8⁺ cells were enriched from fresh PBMC by incubating PBMC with anti-CD8 MACS beads (Miltenyi Biotec, Auburn, CA), followed by separation on a BS-positive selection column. Because the anti-CD8 MACS beads did not occupy all the CD8 sites on the cells, the enriched cells were restained with anti-CD8-allophycocyanin (FL4) so that only high-expressing CD8⁺ T cells were gated for subsequent analysis. We also used an MHC class I peptide tetramer of HLA-B7 containing HCMV pp65 peptide TPRVTGGGAM (gift from Dr. J. Lipolis, National Institutes of Health Core Tetramer Facility, Atlanta, GA).

Purification of cell subpopulations

For clonotypic probing analysis, PBMC were stained with anti-CD8, anti-CD45RA, and anti-CD28 to sort the CD8⁺CD45RA⁻ (CD45RO cells), CD8⁺CD28⁻CD45RA^{high}, and CD8⁺CD28⁺CD45RA^{high} T cell subpopulations using a FACSVantage cell sorter (BD Biosciences). To obtain the CD28⁻CD27⁺ and CD28⁻CD27⁻ subpopulations of CD8⁺ T cells, PBMC were first depleted of CD16⁺ NK cells (by incubation with anti-CD16 IgM (Leu-11b; BD Biosciences) followed by complement) and depleted of CD4⁺ cells with anti-CD4-conjugated MACS microbeads (Miltenyi Biotec). Cells were then stained with anti-CD28-FITC and anti-CD27-PE and sorted into CD28⁻CD27⁻ and CD28⁻CD27⁺ subpopulations by a FACSVantage cell sorter. The purity of lymphocyte populations prepared by FACSVantage cell sorting or MACS microbeads was always >98%.

For functional studies, CD8⁺CD45RO^{high} and CD8⁺CD45RA^{high} cells were prepared from PBMC using negative cell sorting; PBMC were stained with FITC-conjugated anti-CD4, anti-CD19, anti-CD16, and anti-CD56 (to remove CD4⁺ T cells, B cells, and NK cells, respectively) and either anti-CD45RA or anti-CD45RO and sorted for nonstained cells using a FACSVantage cell sorter, yielding CD8⁺CD45RO^{high} and CD8⁺CD45RA^{high} T cell populations, respectively. CD45RA^{high}CD28⁻CCR7⁻CD8⁺ T cells were also prepared by negative cell sorting, following staining with FITC-conjugated anti-CD4, anti-CD19, anti-CD16, anti-CD56, anti-CD45RO, anti-CD28, and anti-CCR7. Aliquots of the negative selected cells were restained with anti-CD8, anti-CD45RA, and anti-CD45RO to confirm their purity, which was >99% for CD45RA^{high} cells and 98–99% for CD45RO^{high} cells. For functional studies, CD28⁻ cells were prepared from PBMC by negative selection using anti-CD28-FITC, followed by anti-FITC MACS microbeads (purity of lymphocyte populations, >98%).

For the functional studies, purified subpopulations of cells were stimulated *in vitro* with irradiated autologous peptide-pulsed PBMC in RPMI plus 10% FCS and 10% human AB serum plus 5 IU/ml human rIL-2 (provided by the Medical Research Council Centralized Facility for AIDS Reagents, National Institute of Biological Standards and Control) and cultured for 14 days, followed by assay of peptide-specific cytotoxicity as previously described (1, 3) and/or analysis by flow cytometry.

Generation of T cell clones and determination of TCR β -chain hypervariable sequence

T cell clones were generated from single-cell cultures by limiting dilution analysis followed by recloning as previously described (3). Total RNA was extracted from each clone, and first-strand cDNA was derived from this before PCR using a panel of 36 TCR β family specific primers together with the corresponding C region-specific primer (synthesized by Genosys, Cambridge, U.K.) as previously described (3). The amplified PCR product from the clonal β amplification was purified (Qiagen, Valencia, CA) and sequenced by automated DNA sequencing (Department of Biochemistry, University of Cambridge, Cambridge, U.K.).

Quantitation of TCR clonotypes in phenotypically defined subpopulations

Complementary 15–20 mer oligonucleotide probes based on the TCR β -chain hypervariable region of immunodominant peptide-specific CTL clones were designed. Such probes are highly specific for individual CTL clonotypes (8). mRNA was extracted from purified subpopulations of cells, reverse transcribed into cDNA, and amplified in duplicate using TCR β -specific PCR primers as described previously. A positive control sample from the original defined CTL clone and a negative control sample from the pooled PBMC of four HCMV- and HIV-seronegative donors were amplified simultaneously in duplicate using the same primers. Each PCR product was separated on an agarose gel and blotted onto a Zeta-probe nylon filter (Bio-Rad, Hercules, CA). After washing and prehybridization, the filter was incubated overnight with a γ - 32 P end-labeled clonotypic probe in hybridization buffer. After washing, the amount of probe that had bound to each sample on the filter was quantitated using an Instant Imager (Beckman Coulter, Palo Alto, CA). The filter was stripped by soaking in 0.4 M NaOH, washed, and then rehybridized with a TCR β -chain constant region probe that detects all TCR sequences. In each subpopulation studied we calculated the relative abundance of the clonotype sequence as a proportion of all TCR sequences of the same β family: relative abundance of clonotype sequence = $100 \times ((\text{cpm clonotypic probe}/\text{cpm TCR constant probe for the T cell population of interest})/(\text{cpm clonotypic probe}/\text{cpm TCR constant probe for the positive control clone}))$

In each purified subpopulation of cells, the clone size was calculated by multiplying the proportion of CD8^+ cells that had the corresponding β segment (determined by flow cytometry) by the relative abundance of the clonotype sequence.

Results

HCMV-specific clones are abundant in $\text{CD28}^- \text{CD45RA}^{\text{high}}$ cells, but not in $\text{CD28}^+ \text{CD45RA}^{\text{high}}$ cells

To determine the expression of CD28 within $\text{CD8}^+ \text{CD45RA}^{\text{high}}$ cells, PBMC from six HCMV-seropositive donors and two EBV-seropositive donors were stained with anti-CD8-allophycocyanin, anti-CD45RO-FITC, anti-CD45RA-TC, and anti-CD28-PE and analyzed by four-color flow cytometry. After gating on CD8^+ T cells, the relationship between the expression of CD45RA and CD28 for a single HCMV carrier is illustrated in Fig. 1A, in which four populations can be identified: 1) a circumscribed population that is $\text{CD28}^+ \text{CD45RA}^{\text{high}}$ (and $\text{CD45RB}^{\text{low}}$ and $\text{CD45RO}^{\text{low}}$; data not shown), 2) a population that is $\text{CD28}^+ \text{CD45RA}^{\text{low/-}} \text{CD45RO}^{\text{high}}$, 3) a small population that is $\text{CD28}^- \text{CD45RA}^- \text{CD45RO}^{\text{high}}$, and 4) a population that is $\text{CD28}^- \text{CD45RA}^{\text{high}} \text{CD45RO}^{\text{low}}$. The relative proportions of CD8^+ cells in each subpopulation varied little from subject to subject. To identify HCMV-specific cells, PBMC were also stained with anti-CD8-allophycocyanin, anti-CD45RA-FITC, anti-CD28-TC, and HLA-B7-HCMVpp65 peptide tetramer-PE. Fig. 1B shows the expression of CD28 and CD45RA after gating on tetramer-staining CD8^+ T cells. Tetramer-





FIGURE 1. A, Expression of pp65 B7 tetramer. Expression of CD28 in relation to CD45RA and expression of CD28 in relation to CD27 gated on all CD8^+ T cells (B and D), or gated on HCMV pp65-specific CD8^+ T cells stained by HLA-B7-peptide tetramer (D and E) in PBMC of healthy HCMV carrier 009. The percentage of CD8^+ tetramer-positive cells in each region is shown.

staining cells were predominantly CD28^- and were almost entirely absent from the $\text{CD28}^+ \text{CD45RA}^{\text{high}}$ population.

We derived peptide-specific single-cell clones from each of the HCMV-seropositive donors, sequenced the hypervariable VDJ region of the TCR β -chain, and designed a clonotypic oligonucleotide probe for each immunodominant peptide-specific clonotype. Using quantitative clonotype probing, we determined the distribution of cells of each virus-specific clone within purified $\text{CD28}^- \text{CD45RA}^{\text{high}}$ or $\text{CD28}^+ \text{CD45RA}^{\text{high}}$ subpopulations prepared from PBMC by cell sorting (Fig. 2). We calculated the number of cells of the clone in PBMC by multiplying the relative



% of clonotype sequence within all $\text{V}\beta 14^+$ sequences

FIGURE 2. Oligonucleotide probing of a virus-specific clone in amplified cDNA from purified subpopulations of PBMC of healthy HCMV carrier 009. I, Probing with a labeled clonotypic probe specific for the hypervariable TCR β -chain sequence of a $\text{V}\beta 14^+$ pp65 peptide-specific CD8^+ T cell clone. II, The filter was stripped and reprobbed with a conserved constant region-specific probe that detects all amplified $\text{V}\beta 14^+$ TCR sequences. The relative abundance of clonotype sequence as a proportion of all TCR sequences of the same $\text{V}\beta 14$ family was calculated as described in the text.

Table II. The percentage of clonotype sequence as a proportion of all TCR sequences of the same V β family in purified subpopulations of CD28⁻CD45RA^{high} or CD28⁺CD45RA^{high} cells

Donor	Peptide	% Clonotype Sequence ^a			Clone Size Per Million Cells of Each Phenotype		Clone Size Per Million CD8 ⁺ Cells in Peripheral Blood		
		Total CD8 (%)	CD28 ⁻ CD45RA (%)	CD28 ⁺ CD45RA (%)	CD28 ⁻ CD45RA	CD28 ⁺ CD45RA	Total CD8	CD28 ⁻ CD45RA	CD28 ⁺ CD45RA
009	HCMV pp65 (aa 417–426)	12	15	0	6170	0	6435	3320	0
	HCMV IE (aa 309–317)	27	21	0	5380	150	400	1480	40
013	HCMV IE (aa 198–207)	27	51	3	18960	530	8850	8040	200
017	HCMV pp65 (aa 187–195)	28	22	1	5500	10	9530	1610	4
018	HCMV pp65 (aa 265–278)	23	12	1	4100	270	14170	2330	150
022	EBV EBNA3c (aa 281–290)	22	40	2	22120	50	4645	4170	15

^a The percentage clonotype sequence as a proportion of all TCR sequences of the same V β family in each purified subpopulation.

proportion of clonotype sequence within all TCR sequences of the same V β family by the proportion of CD8⁺ cells that express the same V β segment determined by flow cytometry. As we had previously found, individual CTL clones that recognized HCMV peptides could be very large (Table II). Clones specific for either HCMV pp65 or IE72 were very abundant in the CD28⁻CD45RA^{high} subpopulation, but were almost entirely absent from the CD28⁺CD45RA^{high} subpopulation (clonotype detection range, 0–3%; close to the limit of detection of the assay within the purity achieved by cell sorting). For comparison with another persistent herpesvirus, we also derived EBV peptide-specific CD8⁺ CTL clones, designed clonotypic probes, and used these to determine the distribution of EBV-specific clones within the same purified T cell subpopulations. An HLA-B4402-restricted EBNA3C-specific clone from one subject was also very abundant in the CD45RO^{high} and the CD28⁻CD45RA^{high} subpopulations, but not in the CD28⁺CD45RA^{high} subpopulation (Table II). HLA-B7-restricted EBNA3C-specific clones from three other subjects were almost entirely distributed within CD45RO^{high} cells (data not shown).


HCMV-specific clonotypes are abundant in both CD28⁻CD27⁺ and CD28⁻CD27⁻ cells

Using four-color flow cytometry, we studied the expression of CD28, CD27, and CD45RA on peripheral blood CD8⁺ T cells (Fig. 3). In six healthy HCMV carriers, the proportion of CD8⁺ T cells that were CD28⁺CD27⁺ ranged from 37 to 66%, the proportion that were CD28⁺CD27⁻ ranged from 1 to 3%, the proportion that were CD28⁻CD27⁺ ranged from 9 to 26%, and the

proportion that were CD28⁻CD27⁻ ranged from 24 to 38%. Thus, the vast majority of CD28⁺CD8⁺ cells were also CD27⁺; the CD28⁺CD27⁻ population was always small. Among CD27⁺ cells, the level of expression of CD27 on CD28⁺ cells was generally higher than that on CD28⁻ cells. We analyzed the expression of CD45RA, CCR7, and CD62L after gating on either CD8⁺CD28⁺ or CD8⁺CD28⁻ cells. The CD8⁺CD28⁻CD27⁺ cells were predominantly CD45RA^{high}, were almost all CCR7⁻, and were 25–65% CD62L⁺ (data not shown). The CD8⁺CD28⁻CD27⁻ cells were also predominantly CD45RA^{high} (Fig. 3), were almost all CCR7⁻, and were 10–55% CD62L⁺ (data not shown).

We examined the distribution of individual clonotypes in the CD28⁻CD27⁻ and CD28⁻CD27⁺ subpopulations of CD8⁺ T cells. Virus-specific clonotype sequences often accounted for a large proportion of all TCR sequences of the same V β family (Fig. 4). For most clones, cells of the clone were distributed in both the CD28⁻CD27⁻ and CD28⁻CD27⁺ subpopulations, and in general, the clone size in 10⁶ cells of each subpopulation was greater in the CD28⁻CD27⁺ subpopulation than in the CD28⁻CD27⁻ subpopulation (Table III). In healthy HCMV carrier 017, an individual HCMV-specific clone 17A was almost entirely partitioned in the CD28⁻CD27⁻ subpopulation, in which it comprised 38–48% of V β 17⁺ sequences; in the CD28⁻CD27⁺ population, this clonotype was consistently very low, close to the limit of detection of the assay (determined by the binding of the clonotypic probe to the negative control sample; Fig. 4B). When purified CD28⁻ PBMC from this donor were stimulated *in vitro* with irradiated

FIGURE 3. Expression of CD27 in relation to CD62L, CCR7, or CD45RA gated on either CD28⁺CD8⁺ T cells or CD28⁻CD8⁺ T cells in PBMC of healthy HCMV carrier 013.






FIGURE 4. Oligonucleotide probing of a virus-specific clone in amplified cDNA from purified subpopulations of PBMC. *I*, Probing with a labeled clonotypic probe specific for the hypervariable TCR β -chain sequence of a V β 6.4⁺ pp65 peptide aa 511–525-specific CD8⁺ T cell clone of healthy HCMV carrier 011. *II*, The filter was stripped and reprobed with a conserved constant region-specific probe that detects all amplified V β 6.4⁺ TCR sequences.

autologous peptide-pulsed PBMC and cultured for 14 days in the presence of exogenous IL-2, there was a strong proliferative response of V β 17⁺CD8⁺ T cells that remained CD28⁻ and CD27⁻ (Fig. 5).

Distinctive patterns of chemokine receptor expression on CD28⁺CD45RA^{high} and CD28⁻CD45RA^{high} subpopulations of CD8⁺ T cells

Recirculation of T cells among blood, secondary lymphoid tissue, and peripheral tissues is an essential part of anti-viral immune surveillance. The complex trafficking of lymphocytes is partly regulated by specific chemokines that bind to chemokine receptors expressed on T cells, and memory and naive T cells would be expected to express distinctive patterns of chemokine receptors. We used four-color flow cytometry to analyze the chemokine receptor expression on CD8⁺CD28⁺CD45RA^{high}, CD8⁺CD28⁺CD45RO^{high}, CD8⁺CD28⁻CD45RO^{high}, and CD8⁺CD28⁻CD45RA^{high} T cells in PBMC derived from six donors,




FIGURE 5. Kinetics of proliferation of CD28⁻CD27⁻V β 17⁺ CD8⁺ T cells following in vitro stimulation of CD28⁻ PBMC from healthy HCMV carrier 017 with specific HCMV pp65 peptide aa 187–195 (representative of two independent experiments).

four of whom were both HCMV-seropositive and EBV-seropositive, using Abs against CCR5, CCR6, CCR7, and CXCR4 shown for a representative donor (Fig. 6). For each of the four T cell subpopulations, the results were generally consistent between individual donors and between the HCMV-seropositive and HCMV-seronegative donors (Table IV).

CD8⁺CD28⁺CD45RA^{high} cells were the most homogeneous population, whereas CD8⁺CD28⁺CD45RO^{high} T cells showed bimodal distributions of expression of CCR5, CCR6, CCR7, and CD62L; this heterogeneity of expression of different surface receptors could potentially give rise to a very complex repertoire of chemokine receptor expression among individual CD8⁺CD28⁺CD45RO^{high} T cells. CD8⁺CD28⁻CD45RA^{high} cells showed variable expression of CXCR4 expression between donors, although the absolute level of CXCR4 expression on CD8⁺CD28⁻CD45RA^{high} cells was low compared with that in the other subpopulations. Many CD8⁺CD28⁻CD45RA^{high} cells expressed CD57; the expression of CD57 was consistently higher in the HCMV-seropositive donors (66–76%) compared with the HCMV-seronegative donors (13–20%).

Table III. The percentage of clonotype sequence as a proportion of all TCR sequences of the same V β family in purified subpopulations of CD28⁻CD27⁻ and CD28⁻CD27⁺ cells

Donor	Peptide	Clonotype	Date of Sample	% Clonotype Sequence ^a						Clone Size Per Million CD8 ⁺ Cells of Each Phenotype		Clone Size Per Million CD8 ⁺ Cells in Peripheral Blood		
				Total CD8 ⁺ cells (%)	Sorted cells		Sorted cells		Total CD8 ⁺ cells	Sorted cells				
					CD28 ⁻ CD27 ⁻ (%)	CD28 ⁻ CD27 ⁺ (%)	CD28 ⁻ CD27 ⁻	CD28 ⁻ CD27 ⁺		CD28 ⁻ CD27 ⁻	CD28 ⁻ CD27 ⁺			
009	HCMV pp65 (aa 417–426)	09A V β 14	07/99	10	9	9	3,200	6,300	7,200	1,000	1,500			
011	HCMV pp65 (aa 495–503)	11A V β 17	07/99	20	73	60	20,000	35,000	12,000	4,800	3,200			
	HCMV pp65 (aa 511–525)	11B V β 6.4	07/99	38	62	48	ND	ND	ND	ND	ND			
017	HCMV pp65 (aa 187–195)	17A V β 17	08/99	12	47	0.5	15,000	220	6,000	4,000	20			
			03/00	9	38	1.0	16,000	10	4,400	3,900	1			
018	HCMV pp65 (aa 495–503)	18A V β 13.1	04/00	0.6	1.3	4	160	330	90	60	60			
	HCMV pp65 (aa 265–274)	18D V β 5.1	04/00	15	6	44	3,500	9,500	6,200	1,300	1,700			

^a The percentage clonotype sequence as a proportion of all TCR sequences of the same V β family in each purified subpopulation.




FIGURE 6. Expression of chemokine receptors, CD62L, CD27, and CD57 on the four subpopulations of CD8⁺ T cells CD28⁺CD45RA^{high}, CD28⁺CD45RO^{high}, CD28⁻CD45RO^{high}, and CD28⁻CD45RA^{high} in PBMC of healthy HCMV carrier 009.

In healthy virus carriers, CD8⁺CD28⁻CD45RA^{high}CCR7⁻ cells are not terminally differentiated

We have previously shown that both the CD45RO^{high} and CD45RA^{high}CD8⁺ T cell populations can respond to peptide-HCMV peptides by proliferation and differentiation into peptide-specific cytotoxic effector T cells that are CD45RO^{high}CD45RA^{low} (8). On the basis of short term culture it has recently been suggested that CD8⁺CD45RA⁺CCR7⁻ cells might be terminally differentiated effector cells (11). To test this hypothesis, we purified CD8⁺CD28⁻CD45RA^{high}CCR7⁻ cells by negative selection to avoid ligation of cell surface CD8 or CD45RA, and as a positive control we also purified CD8⁺CD45RO^{high} cells. Each purified population of cells was stimulated in vitro with irradiated autologous peptide-pulsed PBMC and cultured for 14 days in the presence of exogenous IL-2, followed by assay of peptide-specific cytotoxicity and analysis of surface expression of CD28, CD45RA, CD45RO, CCR5, CCR6, and CCR7 by flow cytometry.

As expected, following stimulation with peptide the CD8⁺CD45RO^{high} cells proliferated, generating a large population of tetramer-positive effector cells that up-regulated CD45RO and showed strong peptide-specific cytotoxicity. These effector cells showed varying levels of CD28 expression, but were CCR5^{high}, CCR6⁻, and CCR7⁻ (Fig. 7). Following stimulation with peptide, purified CD8⁺CD28⁻CD45RA^{high}CCR7⁻ cells also proliferated and differentiated into peptide-specific cytotoxic effector cells. These effector cells down-regulated CD45RA, up-regulated CD45RO, and remained CD28⁻; they were also CCR5^{high}, CCR6⁻, and CCR7⁻.

During acute primary HCMV infection, most pp65-specific CD8⁺ T cells are CD28⁻CD45RO⁺CCR7⁻ and during convalescence they revert to CD28⁻CD45RA⁻CCR7⁻

During acute primary HCMV infection in a single subject we detected activated pp65 peptide-specific cytotoxic CD8⁺ T cells in

unstimulated PBMC; at a standard E:T cell ratio, the magnitude of peptide-specific cytotoxicity was greatest at the peak of symptoms (3 wk after the onset of symptoms) and diminished to low levels by 8 wk after the onset of symptoms (8). We analyzed the expression of CD28 and CD45RO on tetramer-positive CD8⁺ T cells in cryopreserved cells obtained from the same subject during and after acute primary HCMV infection. At the peak of symptoms (3 wk after the onset of symptoms) 80% of the tetramer-positive CD8⁺ cells were CD28⁻CD45RO⁺ and CCR7⁻ (Fig. 8). During convalescence there was a progressive expansion of the CD28⁻CD45RA^{high}CCR7⁻ tetramer-positive population, which may reflect apoptotic death of some highly activated CD28⁻CD45RO⁺ cells and/or redistribution of CD28⁻CD45RA^{high} cells from inflamed tissues to the circulation after resolution of acute disseminated HCMV infection. These findings are in agreement with our previous observation in this subject that cells of an immunodominant pp65-specific CD8⁺ clone were initially abundant in CD45RO⁺ cells, but became progressively enriched in CD45RA⁺ cells during convalescence, consistent with clonal reversion from CD45RO⁺ to CD45RA⁺ with time (8).

Discussion


We found that in healthy HCMV carriers, expanded HCMV-specific CD8⁺ T cell clones are distributed in both CD45RO^{high} and CD28⁻CD45RA^{high} populations and are abundant in both CD27⁺CD28⁻ and CD27⁻CD28⁻ cells. Neither HCMV-specific nor EBV-specific clones are found in the CD28⁺CD45RA^{high} T cell population. We found that in healthy virus carriers, highly purified CD28⁻CD45RA^{high}CCR7⁻ cells are not terminally differentiated, because following stimulation in vitro with specific HCMV peptide these cells underwent sustained clonal proliferation, up-regulated CD45RO and CCR5, and showed strong peptide-specific cytotoxic activity. In an individual with acute primary HCMV infection, pp65-specific CD8⁺ T cells were predominantly

Table IV. The proportion of CD8⁺ cells in each subpopulation that express CCR5, CCR6, CCR7, CXCR4, CD62L, CD27, or CD57^a

Cell Population	% of Positive Cells in Each Subpopulation						
	CCR5	CCR6	CCR7	CXCR4	CD62L	CD27	CD57
CD28 ⁺ CD45RA ^{high}	1–3	7–10	95–99	97–99	91–98	98–100	1–4
CD28 ⁺ CD45RO ^{high}	52–79	29–54	35–42	92–98	18–31	85–96	1–8
CD28 ⁻ CD45RO ^{high}	12–18	10–12	2–4	37–58	12–31	47–54	66–78
CD28 ⁻ CD45RA ^{high}	1–3	1–12	1–3	2–58	13–60	2–28	13–76

^a Range of values observed in seven healthy HCMV carriers.

FIGURE 7. In vitro stimulation of purified CD8⁺CD45RO⁺ (left panels) or CD8⁺CD28⁻CD45RA⁺CCR7⁻ cells (right panels) with autologous irradiated peptide-pulsed PBMC of healthy HCMV carrier 013 leads to peptide-specific proliferation and differentiation. Expression of CD45 isoforms and chemokine receptors and HCMV pp65-specific tetramer staining are shown gated on CD8⁺ T cells before and 14 days after stimulation. Peptide-specific cytotoxic activity was also assayed 14 days after stimulation at an E:T cell ratio of 10:1 against ⁵¹Cr-labeled autologous or MHC mismatched lymphoblastoid target cells pulsed with HCMV pp65 peptide or unpulsed.



CD28⁻CD45RO^{high} and almost entirely lacked expression of CCR7; during convalescence, an increasing proportion of pp65-specific CD8⁺ T cells were CD28⁻CD45RA^{high}CCR7⁻.

The current study adds to the evidence that the cells of a single expanded Ag-experienced CD8⁺ T cell clone are very heterogeneous in phenotype in vivo, reflecting many states of activation/differentiation (3, 8). Naive cells are CD28⁺CD45RA^{high}CCR7⁺CD62L⁺CD27⁺ and CD11a^{low}. Following activation by Ag, all daughter cells permanently up-regulate CD11a (proposed in Ref. 12) and up-regulate CD45RO, at least initially. Some daughter cells remain CD28⁺CD45RO⁺CCR7⁺; these cells have been termed central memory cells (10). CD45RO⁺CCR7⁻ cells have been termed effector memory cells (10). Our results show that these cells are, in fact, made up of two subpopulations of daughter cells, namely CD28⁺CD45RO⁺CCR7⁻ and CD28⁻CD45RO⁺CCR7⁻, that also differ in the expression of CD57. The precise relationship among these three different populations of CD45RO⁺ cells requires further study; it is unclear whether CD28⁻CD45RO⁺ cells can arise directly from activated naive cells or via intermediate CD28⁺CD45RO⁺ cells. CD28⁻CD45RO⁺CCR7⁻ cells predominate in peripheral blood during acute primary HCMV infection and revert to CD28⁻CD45RA⁺CCR7⁻ cells in convalescence; on CD28⁻CD45RA⁺ cells, the pattern of surface expression of a wide range of chemokine receptors and adhesion molecules closely resembles that on CD28⁻CD45RO⁺ cells. The factors that lead to the transition from CD28⁻CD45RO⁺ to CD28⁻CD45RA⁺ are not yet understood. Our results show that when CD28⁻CD45RA⁺CCR7⁻ cells are activated by peptide Ag in vitro, they proliferate, remain CD28⁻, and up-regulate CD45RO and CCR5. The circulating CD28⁻CD45RO⁺CCR7⁻ population, some of which express CCR5, is relatively rich in HCMV tetramer-positive cells (Fig. 1) and may include cells that have recently been activated by exposure to HCMV Ag in vivo.

The generation of phenotypic diversity within the clonal progeny of a single virus-specific cell may be an instructive process as a result of differences in the activation state of APC to which the naive cell and later daughter cells are exposed (15, 16) and differences in the cytokine milieu during their activation and differentiation (17). An alternative possibility is that activation of a single CD8⁺ T cell might give rise to daughter cells of different phenotypes by a stochastic process. In either case, the diversity of phenotypes may be modified by subsequent selection of those daughter cells whose activation state and/or homing pathway are best suited to control the virus at a given site. In the case of a persistent virus that infects cells in different tissues, we speculate that those viral Ags expressed in nonlymphoid tissues such as the intestine or respiratory tract may evoke specific CD8⁺ T cells that have a different phenotype and pathway of recirculation compared with other viral Ags expressed in lymphoid tissues. Whereas CD8⁺ T cell clones specific for the HCMV structural protein pp65 are abundant in CD28⁻CD45RA^{high} cells, it is interesting that in the same donor the phenotype of expanded CD8⁺ T cell clones specific for EBV EBNA3C expressed in latently infected B cells was dominated by CD45RO⁺ cells and included very few CD28⁻CD45RA^{high} cells.

Our finding of the same clonotype in both CD28⁻CD27⁺ and CD28⁻CD27⁻ subpopulations confirms that these subsets represent different activation states of the same lineage (18). Loss of CD27 expression on CD8⁺ T cells is associated with increased expression of perforin and granzyme B and cytotoxic activity in the absence of prior restimulation in vitro. It has been suggested that these CD27⁻ cells might be terminally differentiated and possibly incapable of further cell division (18). Our results (Fig. 5) show that following stimulation with specific peptide, the CD28⁻CD27⁻ population contains cells that are capable of sustained proliferation in vitro; the ability of CD28⁻CD27⁻ cells to proliferate




FIGURE 8. In acute primary HCMV infection, most circulating HCMV pp65-specific CD8⁺ T cells are CD28⁻CD45RO⁺ and, during convalescence, they revert to CD28⁻CD45RA⁺. PBMC obtained at 3, 4, and 8 wk after the onset of symptoms were analyzed by four-color flow cytometry. The expression of CD28 in relation to CD45RO, the percentage of CD8⁺ cells in each quadrant (A), and the percentage of CD8⁺ pp65 B7 tetramer-positive cells in each quadrant (B), the expression of CCR7 in relation to CD45RO, the percentage of CD8⁺ cells in each quadrant (C), and the percentage of CD8⁺ pp65 B7-tetramer positive cells in each quadrant (D) are shown.


in vitro may depend on the specific experimental conditions used, in particular the provision of autologous APC and exogenous IL-2 (19). It has previously been suggested that the CD27⁺CD45RA^{high} population of human CD8⁺ T cells may represent naive cells (9). However, we found that expanded pp65-specific clones were abundant in both CD27⁺CD28⁻ and CD27⁻CD28⁻ cells. Thus, for human CD8⁺ T cells the phenotype CD27⁺CD45RA^{high} should not be used to identify naive cells; CD27⁺CD45RA^{high} cells do contain naive cells, but also contain a significant subpopulation of CD28⁻CD27⁺ Ag-experienced expanded clones. In general, among CD8⁺ T cells that express CD27, those cells that are

CD28⁺ express a higher level of CD27 compared with CD28⁻ cells (Fig. 3). Our results are consistent with those of Kern et al. (20), who demonstrated that the CD27^{int} population contained many more HCMV-specific cells than the CD27^{high} population. In the paper that proposed that CD27⁺CD45RA^{high} cells might represent naive CD8⁺ T cells, the CD27⁺CD45RA^{high} population did, in fact, contain a significant population of CD27^{int} cells that stained positively for intracellular perforin and granzyme B (Fig. 6 of Ref. 9), which probably correspond to the Ag-experienced CD27⁺CD28⁻ clones we describe.

Our results disagree with the recent suggestion that CD45RA^{high}CCR7⁻ cells might be terminally differentiated effector cells (11). Champagne et al. (11) reported that CD45RA⁺CCR7⁻ cells failed to proliferate in response to stimulation with a combination of anti-CD3 and anti-CD28; this is not surprising, because as we have shown almost all CD45RA⁺CCR7⁻ cells lack the expression of CD28. In contrast, when we stimulated purified CD28⁻CD45RA⁺CCR7⁻ cells with fresh autologous peptide-pulsed APC, we observed strong proliferative responses accompanied by up-regulation of CD45RO. This difference in functional response is probably due to experimental conditions. We used fresh CD28⁻CD45RA⁺CCR7⁻ cells and studied the response over 14 days because of the kinetics of proliferation of CD28⁻ cells in response to peptide stimulation (Fig. 5), whereas in equivalent experiments Champagne et al. (11) used cryopreserved cells and studied the response for the first 96 h only.

The adhesion molecule and chemokine receptor expression by CD28⁺CD45RA^{high} cells is that expected of naive CD8⁺ T cells, namely, high expression of CD62L, CCR7, and CXCR4, which favor recirculation through lymph nodes via interaction with high endothelial addressins, secondary lymphoid chemokine or macrophage inflammatory protein-3 β (MIP-3 β), and stromal cell-derived factor-1, respectively. CD28⁺CD45RO⁺ cells have a complex pattern of homing molecule expression; some express one or more receptors that favor recirculation through lymph nodes (CD62L with or without CCR7), while others constitutively express CCR5 and/or CCR6, which would favor recruitment into inflamed tissues where MIP-1 α , MIP-1 β , and RANTES or MIP-3 α are expressed. Almost all CD28⁻CD45RA^{high} cells lack CCR7, most express little or no CXCR4, and a minority express CD62L, which suggests that recirculation through uninfamed lymph nodes may be less efficient; almost all CD28⁻CD45RA^{high} cells lack constitutive expression of CCR5 and CCR6. Faint et al. (12) reported a greater proportion of HCMV tetramer-positive CD45RA^{high} cells in cells derived from

FIGURE 9. A model of the differentiation of human CD8⁺ T cells. Following activation of a CD28⁺CD45RA^{high} naive cell by Ag, CD11a is up-regulated permanently, and CD45RO is up-regulated at least initially. Whether CD28^{minus}CD45RO⁺ cells arise directly from activated naive cells or via CD28⁺CD45RO⁺ cells is unclear. With time, CD28⁻CD45RO⁺ cells revert to CD28⁻CD45RA^{high}; upon subsequent re-exposure to Ag, CD28⁻CD45RA^{high}CCR7⁻ cells proliferate and give rise to CD28⁻CD45RO⁺ cells.



liver compared with cells from lymph node, consistent with preferential recirculation of CD28⁻CD45RA^{high} cells through nonlymphoid tissues. The up-regulation of CCR5 on CD28⁻CD45RA^{high} cells following activation in vitro suggests that these cells may express additional homing receptors when they migrate into tissues in which viral Ag is expressed during HCMV reactivation from latency.

It remains an important challenge to relate the phenotype of a CD8⁺ T cell to its functional role in vivo. From many years there has been a binary functional classification of Ag-experienced T cells as either effector cells or memory cells (21). In this classification effector cells are generated early in the immune response and then decline rapidly, show immediate ex vivo cytotoxicity, and upon transfer into recipients can control acute infection, but not chronic infection, whereas memory cells are generated later in the immune response, do not show immediate ex vivo cytotoxicity, and upon transfer into recipients fail to control acute infection, but do control chronic infection, because they proliferate in response to Ag and differentiate into effector cells. An important limitation of this classification is that the effector activity of a given cell is an all-or-none property, whereas subsequent experimental data from purified populations of Ag-specific T cells assayed directly ex vivo indicate that the cytotoxic activity of an Ag-specific T cell in vivo is, in fact, a quantitative variable. Following the primary immune response, the magnitude of cytotoxic activity per cell varies between Ag-specific T cells purified from different tissues at a given time point (22), and in the spleen cytotoxic activity per cell tends to decrease (by up to 8-fold) with time after Ag exposure (23). Similarly, compared with that seen during primary HCMV infection (8), the magnitude of virus-specific cytotoxicity per cell shown by tetramer-positive CD8⁺ T cells purified from PBMC of healthy carriers of HCMV was modest (7). In unstimulated CD8⁺ T cells in PBMC of healthy adults, staining of intracellular perforin also shows a continuous spectrum, with highest levels in CD27⁻CD45RA⁺ cells (9) or CD11a^{high}CD45RA⁺ cells (12). Thus in long term memory, Ag-experienced daughter cells of a single clone exhibit a spectrum of states of activation/differentiation that include quantitative (rather than qualitative) differences in levels of cytotoxicity. Because the mutually exclusive categories of effector cell and memory cell are no longer adequate to describe the complexity of Ag-experienced cells, the term effector memory cell has been introduced to describe effector cells found in long term memory, which may differ from the effector cells in acute virus infection in their susceptibility to apoptosis and capacity for proliferation. The term effector memory cells was originally applied to CD45RO⁺CCR7⁻ cells (10), but this nomenclature may lead to confusion, because CD45RO⁺CCR7⁻ cells are made up of both CD28⁺ and CD28⁻ cells, and effector-phenotype cells are also abundant in CD27⁻CD45RA⁺ cells (9) or CD11a^{high}CD45RA⁺ cells (12). Rather than descriptive terms, we favor a more precise classification based directly on the expression of sets of surface molecules that reflect the diversity of cellular differentiation.

There is also heterogeneity among the activated effector T cells generated in acute virus infection. Many acutely activated cytotoxic cells (in blood, spleen, or infected peripheral tissues) fail to proliferate in vitro and die rapidly by apoptosis (24). However, a subpopulation of Ag-specific cytotoxic cells can survive in vitro and give rise to long term memory in vivo (25). Cytotoxic effector cells generated by strong antigenic stimulation in vitro can also give rise to progeny that are capable of sustained proliferation in vivo (26). It will be of particular

interest to identify the phenotype(s) of the subpopulation of effector cells in acute virus infection in vivo that is destined not to die, but to give rise to long term memory. Based on the results presented in this paper, our current model of human CD8⁺ T cell differentiation is illustrated in Fig. 9.

We conclude that naive human CD8⁺ T cells are CD28⁺CD45RA^{high}, express CCR7 but not CCR6, and are predominantly CD27⁺ and L-selectin CD62L⁺. The phenotype CD27⁺CD45RA^{high} should not be used to identify naive human CD8⁺ T cells, because in addition to naive cells, CD27⁺CD45RA^{high} cells contain a significant subpopulation of CD28⁻CD27⁺ Ag-experienced expanded clones. CD8⁺ T cell memory to HCMV is maintained by cells of expanded HCMV-specific clones that show heterogeneity of activation state and costimulation molecule expression within both CD45RO^{high} and CD28⁻CD45RA^{high} T cell pools, which may make complementary contributions to the aggregate memory response in vivo.

Acknowledgments

We thank Ray Hicks and Andrew Riddell for flow cytometry cell sorting and advice.

References

- Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. *J. Virol.* 70:7569.
- Kern, F., I. P. Surel, N. Faulhaber, C. Frommel, J. Schneider-Mergener, C. Schonemann, P. Reinke, and H. D. Volk. 1999. Target structures of the CD8⁺ T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. *J. Virol.* 73:8179.
- Weekes, M. P., M. R. Wills, K. Mynard, A. J. Carmichael, and J. G. P. Sissons. 1999. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. *J. Virol.* 73:2099.
- Akbar, A. N., L. Terry, A. Timms, P. C. Beverley, and G. Janossy. 1988. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. *J. Immunol.* 140:2171.
- Merkenschlager, M., L. Terry, R. Edwards, and P. C. Beverley. 1988. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation. *Eur. J. Immunol.* 18:1653.
- Callan, M. F., L. Tan, N. Anells, G. S. Ogg, J. D. Wilson, C. A. O'Callaghan, N. Steven, A. J. McMichael, and A. B. Rickinson. 1998. Direct visualization of antigen-specific CD8⁺ T cells during the primary immune response to Epstein-Barr virus in vivo. *J. Exp. Med.* 187:1395.
- Gillespie, G. M., M. R. Wills, V. Appay, C. O'Callaghan, M. Murphy, N. Smith, P. Sissons, S. Rowland-Jones, J. I. Bell, and P. A. Moss. 2000. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8⁺ T lymphocytes in healthy seropositive donors. *J. Virol.* 74:8140.
- Wills, M. R., A. J. Carmichael, M. P. Weekes, K. Mynard, G. Okecha, R. Hicks, and J. G. Sissons. 1999. Human virus-specific CD8⁺ CTL clones revert from CD45RO^{high} to CD45RA^{high} in vivo: CD45RA^{high}CD8⁺ T cells comprise both naive and memory cells. *J. Immunol.* 162:7080.
- Hamann, D., P. Baars, M. H. G. Rep, B. Hooibrink, S. R. Kerkhof-Garde, M. R. Klein, and R. A. W. vanLier. 1997. Phenotypic and functional separation of memory and effector human CD8⁺ T cells. *J. Exp. Med.* 186:1407.
- Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401:708.
- Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. *Nature* 410:106.
- Faint, J. M., N. E. Anells, S. J. Curnow, P. Shields, D. Pilling, A. D. Hislop, L. Wu, A. N. Akbar, C. D. Buckley, P. A. Moss, et al. 2001. Memory T cells constitute a subset of the human CD8⁺CD45RA⁺ pool with distinct phenotypic and migratory characteristics. *J. Immunol.* 167:212.
- D'Souza, S., D. Rimoldi, D. Lienard, F. Lejeune, J. C. Cerottini, and P. Romero. 1998. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2⁺ melanoma patients have a memory phenotype. *Int. J. Cancer* 78:699.
- Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. *Nat. Med.* 5:677.
- Langenkamp, A., M. Messi, A. Lanzavecchia, and F. Sallusto. 2000. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. *Nat. Immunol.* 1:311.

16. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of interleukin 10-producing, nonproliferating CD4⁺ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. *J. Exp. Med.* 192:1213.
17. Labalette, M., E. Leteurre, C. Thumerelle, C. Grutzmacher, B. Tourvieuille, and J. P. Dessaint. 1999. Peripheral human CD8⁺CD28⁺ T lymphocytes give rise to CD28⁻ progeny, but IL-4 prevents loss of CD28 expression. *Int. Immunol.* 11:1327.
18. Hintzen, R. Q., R. de Jong, S. M. Lens, M. Brouwer, P. Baars, and R. A. van Lier. 1993. Regulation of CD27 expression on subsets of mature T-lymphocytes. *J. Immunol.* 151:2426.
19. Weekes, M. P., A. J. Carmichael, M. R. Wills, K. Mynard, and J. G. P. Sissons. 1999. Human CD28⁻CD8⁺ T cells contain greatly expanded functional virus-specific memory CTL clones. *J. Immunol.* 162:7569.
20. Kern, F., E. Khatamzas, I. Surel, C. Frommel, P. Reinke, S. L. Waldrop, L. J. Picker, and H. D. Volk. 1999. Distribution of human CMV-specific memory T cells among the CD8^{pos} subsets defined by CD57, CD27, and CD45 isoforms. *Eur. J. Immunol.* 29:2908.
21. Volkert, M., O. Marker, and K. Bro-Jorgensen. 1974. Two populations of T lymphocytes immune to the lymphocytic choriomeningitis virus. *J. Exp. Med.* 139:1329.
22. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. *Science* 291:2413.
23. Zimmerman, C., K. Brduscha-Riem, C. Blaser, R. M. Zinkernagel, and H. Pircher. 1996. Visualization, characterization, and turnover of CD8⁺ memory T cells in virus-infected hosts. *J. Exp. Med.* 183:1367.
24. Akbar, A. N., M. Salmon, J. Savill, and G. Janossy. 1993. A possible role for *bcl-2* in regulating T-cell memory: a "balancing act" between cell death and survival. *Immunol. Today* 14:526.
25. Jacob, J., and D. Baltimore. 1999. Modelling T-cell memory by genetic marking of memory T cells in vivo. *Nature* 399:593.
26. Opferman, J. T., B. T. Ober, and P. G. Ashton-Rickardt. 1999. Linear differentiation of cytotoxic effectors into memory T lymphocytes. *Science* 283:1745.